Koyfin Home > Directory > Health Care > Revance Therapeutics > Levered Free Cash Flow (FCF)

Revance Therapeutics Levered Free Cash Flow (FCF) Chart (RVNC)

Revance Therapeutics annual/quarterly Levered Free Cash Flow (FCF) from 2013 to 2020.
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the quarter ending June 06, 2020 was $-23m a -65.40% increase of 15m year over year
  • Revance Therapeutics Levered Free Cash Flow (FCF) for the last 12 months ending June 06, 2020 was $-103m a 14.32% decrease of -15m year over year
  • Revance Therapeutics Annual Levered Free Cash Flow (FCF) for 2019 was $-54m a -76.05% increase of 41m from 2018
  • Revance Therapeutics Annual Levered Free Cash Flow (FCF) for 2018 was $-95m a 43.29% decrease of -41m from 2017
  • Revance Therapeutics Annual Levered Free Cash Flow (FCF) for 2017 was $-54m a 28.70% decrease of -15m from 2016
Other Cash Flow Metrics:
  • Revance Therapeutics Cash Flow from Operations for the quarter ending September 09, 2018 was $-25m a -11.78% increase of 3m year over year
  • Revance Therapeutics Total Revenue for the quarter ending September 09, 2018 was $2m a 98.43% increase of 2m year over year
View Chart On Koyfin

Quarterly RVNC Levered Free Cash Flow (FCF) Data

06/2020$-23m
03/2020$-31m
12/2019$-12m
09/2019$-37m
06/2019$-11m
03/2019$6m
12/2018$-46m
09/2018$-14m
06/2018$-17m
03/2018$-18m

Annual RVNC Levered Free Cash Flow (FCF) Data

2019$-54m
2018$-95m
2017$-54m
2016$-38m
2015$-33m
2014$-54m
2013$-30m
2012$-18m